Streetbeat News

Earnings

ARRY

Array Technologies' shares are trading higher after the company reported better than expected Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:23 pm

AHOTF

American Hotel Inc Props (OTC:AHOTF) reported Q2 earnings of $0.19 per share, a 5.56% increase YoY. However, sales decreased by 0.22% to $75.48 million compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 08, 2023 | 10:16 pm

APPS

Digital Turbine has projected its Q4 adjusted EPS to be between $0.13 and $0.15, lower than the estimated $0.17. The company also expects its revenue to be between $141M and $149M, which is less than the estimated $150.31M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:13 pm

GRND

Grindr Inc. (NYSE:GRND), the world's largest social network for the LGBTQ community, has announced that it will reschedule its second quarter 2023 earnings release and conference call, previously scheduled for August 9, 2023. The new date and time will be announced in a subsequent press release.

Portfolio Pulse from Happy Mohamed

August 08, 2023 | 10:12 pm

LMNL

Liminal BioSciences reported its Q2 2023 financial results, with cash and cash equivalents of $19.3 million and working capital of $16.4 million. R&D expenses increased by $0.4 million due to the advancement of GPR84 and OXER1 antagonist programs. Administration expenses were $4.8 million, with a decrease of $0.3 million. The net loss from continuing operations was $9.0 million, an increase from $6.3 million in Q2 2022. The total loss from discontinued operations was $0.2 million.

Portfolio Pulse from Happy Mohamed

August 08, 2023 | 10:11 pm

PSTX

Poseida Therapeutics reported Q2 earnings with losses of $(0.32) per share, a 53.62% increase YoY. The company also reported $20.01M in sales, a 641.22% increase YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:09 pm

LUXH

LuxUrban Hotels reported Q2 adjusted earnings of $0.05 per share, beating the estimate of $0.04. The company's sales also surpassed estimates, coming in at $31.86M against the expected $29.17M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:09 pm

UBX

Unity Biotechnology reported Q2 losses of $(0.85) per share, beating the analyst consensus estimate of $(0.86) by 1.16 percent. This represents a 55.26 percent increase over losses of $(1.90) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:08 pm

RNA

Avidity Biosciences reported Q2 earnings per share (EPS) of $(0.66), beating the analyst consensus estimate of $(0.80) by 17.5%. This is a 28.26% increase over losses from the same period last year. The company also reported quarterly sales of $2.32 million, beating the analyst consensus estimate of $2.14 million by 8.22%. This is a 6.34% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:04 pm

CTKB

Cytek Biosciences reported Q2 earnings per share (EPS) of $(0.03), missing the analyst consensus estimate of $0.03 by 200 percent. However, the company's quarterly sales of $49.69 million beat the estimate of $45.71 million by 8.71 percent.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:04 pm